NCT05495828 2023-10-26Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase InhibitorsPeking University People's HospitalUnknown30 enrolled
NCT05014100 2021-08-27Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell LymphomaPuyang Oilfield General HospitalPhase 2 Unknown55 enrolled